ClassID:

109193

C12N2310/351 - page 3 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure; Nature of the modification Conjugate

Recent Application in this class:
#601
20220251556
2022-08-11

Enhanced oligonucleotides for inhibiting RTEL1 expression

#602
20220249678
2022-08-11

PEGylated synthetic KL4 peptide, Compositions and Methods Thereof

#603
20220249673
2022-08-11

Phosphonate-Drug Conjugates

#604
20220243200
2022-08-04

COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION

#605
20220235361
2022-07-28

RNAi Inhibition of Alpha-ENaC Expression

#606
20220235359
2022-07-28

NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE

#607
20220228144
2022-07-21

SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#608
20220228141
2022-07-21

OLIGONUCLEOTIDES FOR DGAT2 MODULATION

#609
20220218829
2022-07-14

NUCLEIC ACID CONJUGATES AND USES THEREOF

#610
20220213486
2022-07-07

COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#611
20220213480
2022-07-07

Targeted inhibition using engineered oligonucleotides

#612
20220213476
2022-07-07

Oral delivery of antisense conjugates targeting PCSK9

#613
20220213473
2022-07-07

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE

#614
20220211738
2022-07-07

Nanoparticle to target cancer

#615
20220204976
2022-06-30

RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use

#616
20220202847
2022-06-30

HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#617
20220195436
2022-06-23

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL

#618
20220195434
2022-06-23

Oversubscription scheduling

#619
20220195433
2022-06-23

RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

#620
20220186222
2022-06-16

Linkage modified oligomeric compounds and uses thereof

#621
20220184216
2022-06-16

INTRACELLULAR TARGETING OF MOLECULES

#622
20220184112
2022-06-16

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#623
20220177893
2022-06-09

COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION

#624
20220177888
2022-06-09

Modified short interfering nucleic acid (siNA) molecules and uses thereof

#625
20220177884
2022-06-09

Oligonucleotides for modulating Tau expression

#626
20220177880
2022-06-09

DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS

#627
20220175956
2022-06-09

HAIRPIN-LIKE OLIGONUCLEOTIDE-CONJUGATED SPHERICAL NUCLEIC ACID

#628
20220175813
2022-06-09

Methods for treating or preventing ophthalmological conditions

#629
20220170025
2022-06-02

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM

#630
20220170023
2022-06-02

Modulation of prekallikrein (PKK) expression

#631
20220170016
2022-06-02

Nucleic acids for inhibiting expression of LPA in a cell

#632
20220170015
2022-06-02

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

#633
20220162649
2022-05-26

NOVEL NUCLEIC ACID MODIFIERS

#634
20220162597
2022-05-26

Compound for treatment of heart failure

#635
20220160884
2022-05-26

OLIGONUCLEOTIDE-POLYMER MIKTOARM CONJUGATES AND METHODS OF USE

#636
20220160880
2022-05-26

ANTISENSE NUCLEIC ACID TARGETING PCSK9

#637
20220146496
2022-05-12

Oligonucleotides for inducing paternal UBE3A expression

#638
20220143068
2022-05-12

RNA and nucleic acid carrier including the same

#639
20220135974
2022-05-05

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF PROS1 IN A CELL

#640
20220127613
2022-04-28

Functionally-Modified Oligonucleotides And Subunits Thereof

#641
20220127605
2022-04-28

NUCLEIC ACID CONJUGATE

#642
20220127604
2022-04-28

REVERSIR TM COMPOUNDS

#643
20220119820
2022-04-21

COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING

#644
20220119815
2022-04-21

ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#645
20220112505
2022-04-14

RNAi Inhibition of Alpha-ENaC Expression

#646
20220112493
2022-04-14

PHOSPHONOACETATE GAPMER OLIGONUCLEOTIDES

#647
20220112491
2022-04-14

PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS

#648
20220106599
2022-04-07

Antiviral agents

#649
20220106593
2022-04-07

Multi-targeted single entity conjugates

#650
20220098581
2022-03-31

Methods for Oral Delivery of Oligonucleotides

#651
20220090077
2022-03-24

RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use

#652
20220090069
2022-03-24

OLIGONUCLEOTIDES FOR HTT-1A MODULATION

#653
20220090068
2022-03-24

Complement component C5 iRNA compositions and methods of use thereof

#654
20220090067
2022-03-24

Products and compositions

#655
20220073921
2022-03-10

APTAMER AND USE OF THE APTAMER IN THE DIAGNOSIS AND TREATMENT OF CANCER

#656
20220064640
2022-03-03

DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES CONTAINING A TRILOOP

#657
20220064639
2022-03-03

Compounds and methods for reducing ATXN2 expression

#658
20220062427
2022-03-03

NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF

#659
20220056454
2022-02-24

RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use

#660
20220056451
2022-02-24

HBV BINDING OLIGONUCLEOTIDES AND METHODS OF USE

#661
20220056448
2022-02-24

Modified double-stranded RNA agents

#662
20220056444
2022-02-24

PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS

#663
20220056442
2022-02-24

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

#664
20220056441
2022-02-24

RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA)

#665
20220049252
2022-02-17

CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

#666
20220042022
2022-02-10

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION

#667
20220042014
2022-02-10

APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#668
20220042011
2022-02-10

ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9

#669
20220033825
2022-02-03

POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF

#670
20220033817
2022-02-03

Targeting Ligands

#671
20220033814
2022-02-03

METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY

#672
20220025377
2022-01-27

PRODUCTS AND COMPOSITIONS

#673
20220025376
2022-01-27

Antisense oligomers targeting PCSK9

#674
20220025370
2022-01-27

OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE

#675
20220025367
2022-01-27

NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL8

#676
20220025366
2022-01-27

Compounds and methods for reducing prion expression

#677
20220017902
2022-01-20

METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER

#678
20220017899
2022-01-20

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL

#679
20220002734
2022-01-06

POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF

#680
20220002731
2022-01-06

Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases

#681
20220002727
2022-01-06

MODIFIED DOUBLE-STRANDED RNA AGENTS

#682
20220002722
2022-01-06

NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL

#683
20220002721
2022-01-06

Antisense RNA targeting PMP22 for the treatment of Charcot-Marie-Tooth 1A disease

#684
20210403919
2021-12-30

Aptamers for personal health care applications

#685
20210403913
2021-12-30

CXCL8 Binding Nucleic Acids

#686
20210401994
2021-12-30

SiRNA conjugate, preparation method therefor and use thereof

#687
20210395745
2021-12-23

RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION

#688
20210395737
2021-12-23

METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A)

#689
20210395734
2021-12-23

COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION

#690
20210395729
2021-12-23

Compositions and methods for Editing Nucleic Acids in Cells Utilizing Oligonucleotides

#691
20210388353
2021-12-16

Oligomers

#692
20210380980
2021-12-09

Methods and Compositions for the ADAR-Mediated Editing of SERPINA1

#693
20210380979
2021-12-09

MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE

#694
20210369863
2021-12-02

Method of delivering genes and drugs to a posterior segment of an eye

#695
20210369757
2021-12-02

Methods for treating or preventing ophthalmological conditions

#696
20210363523
2021-11-25

OLIGONUCLEOTIDES FOR MAPT MODULATION

#697
20210355493
2021-11-18

OLIGONUCLEOTIDE MEDIATED NO-GO DECAY

#698
20210348168
2021-11-11

Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome

#699
20210348162
2021-11-11

Compositions and methods for inhibiting expression of the LECT2 gene

#700
20210340535
2021-11-04

Dual-acting siRNA based modulation of C9orf72

#701
20210332367
2021-10-28

KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#702
20210332361
2021-10-28

Aptamer therapeutics useful in the treatment of complement-related disorders

#703
20210332358
2021-10-28

MINIATURIZED HAIRPIN RNAi TRIGGERS (mxRNA) AND METHODS OF USES THEREOF

#704
20210317458
2021-10-14

POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF

#705
20210317457
2021-10-14

ANTISENSE OLIGONUCLEOTIDE (ASO) MOLECULES AND USES THEREOF FOR CORONAVIRUS DISEASES

#706
20210317452
2021-10-14

SERPINA1 iRNA compositions and methods of use thereof

#707
20210315996
2021-10-14

PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING

#708
20210310006
2021-10-07

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#709
20210301294
2021-09-30

RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use

#710
20210299060
2021-09-30

CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES

#711
20210292768
2021-09-23

COMPOSITIONS AND AGENTS AGAINST NONALCOHOLIC STEATOHEPATITIS

#712
20210292763
2021-09-23

COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR

#713
20210292759
2021-09-23

Method for producing dextran polymer-based, amplified nucleic acid aptamer nanoconstruct selectively capturing target molecule

#714
20210292756
2021-09-23

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

#715
20210292352
2021-09-23

Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)

#716
20210285003
2021-09-16

Methods for treating hypercholesterolemia

#717
20210285000
2021-09-16

COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION

#718
20210277401
2021-09-09

Compositions and methods for modulating PKK expression

#719
20210277400
2021-09-09

Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof

#720
20210269803
2021-09-02

OLIGONUCLEOTIDE-BASED PROTEOLYSIS TARGETING CHIMERA

#721
20210269796
2021-09-02

Serpina1 iRNA compositions and methods of use thereof

#722
20210261968
2021-08-26

RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS

#723
20210261961
2021-08-26

ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1

#724
20210261959
2021-08-26

Complement component C3 iRNA compositions and methods of use thereof

#725
20210254076
2021-08-19

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#726
20210254063
2021-08-19

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#727
20210254059
2021-08-19

LINKAGE MODIFIED OLIGOMERIC COMPOUNDS

#728
20210252106
2021-08-19

Methods of improving anemias by combining agents

#729
20210252039
2021-08-19

Compounds and methods for increasing STMN2 expression

#730
20210246492
2021-08-12

INTRACELLULAR ABSEQ

#731
20210238608
2021-08-05

Oligonucleotides for modulating SCN9A expression

#732
20210238607
2021-08-05

SHORT INTERFERING RNA TARGETING VARIANT C1858T OF GENE PTPN22

#733
20210238606
2021-08-05

PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

#734
20210238602
2021-08-05

RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use

#735
20210238601
2021-08-05

Oligonucleotide Conjugates

#736
20210238594
2021-08-05

Compositions and methods for improving strand biased

#737
20210238591
2021-08-05

Selective antisense compounds and uses thereof

#738
20210236651
2021-08-05

General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles

#739
20210236645
2021-08-05

Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids

#740
20210230602
2021-07-29

Composition for inhibiting CTGF expression

#741
20210230599
2021-07-29

STEM-LOOP COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN-8

#742
20210230592
2021-07-29

Targeted Self-Assembly of Functionalized Carbon Nanotubes on Tumors

#743
20210230586
2021-07-29

Expanding the chemical substrates for genetic code reprogramming

#744
20210222176
2021-07-22

POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF

#745
20210214725
2021-07-15

COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#746
20210213136
2021-07-15

Targeting PAX2 for the treatment of breast cancer

#747
20210207146
2021-07-08

Compositions and methods for modulating growth hormone receptor expression

#748
20210198663
2021-07-01

Nanowires/Microscale Pyramids (NWs/MPs) Complex Structure, Method for manufacturing the Same and Its Applications to Isolation of Circulating tumor cells (CTCs) and Detection of Epstein-Barr virus (EBV) DNA

#749
20210189400
2021-06-24

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

#750
20210189398
2021-06-24

AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME

#751
20210189394
2021-06-24

Targeting ligands for therapeutic compounds

#752
20210187007
2021-06-24

C/EBP ALPHA SARNA COMPOSITIONS AND METHODS OF USE

#753
20210186934
2021-06-24

COMPOSITIONS AND USES THEREOF

#754
20210180066
2021-06-17

Compositions and methods for inhibiting gene expression of Hif2alpha

#755
20210180065
2021-06-17

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

#756
20210180064
2021-06-17

Exon skipping compositions for treating muscular dystrophy

#757
20210180063
2021-06-17

ANTI-ARID3A TREATMENTS FOR INFLAMMATORY DISORDERS

#758
20210180054
2021-06-17

Compound for treatment of heart failure

#759
20210171956
2021-06-10

Glucokinase (GCK) iRNA compositions and methods of use thereof

#760
20210170032
2021-06-10

Antisense nucleic acid targeting PCSK9

#761
20210169915
2021-06-10

POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF

#762
20210163952
2021-06-03

TMPRSS6 iRNA compositions and methods of use thereof

#763
20210163945
2021-06-03

Aptamers for targeting coagulation factor XIII and uses thereof

#764
20210154309
2021-05-27

PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX OF CHEMICALLY-MODIFIED siRNA AND SCHIZOPHYLLAN

#765
20210147850
2021-05-20

OLIGONUCLEOTIDES FOR MODULATING RTEL1 EXPRESSION

#766
20210147838
2021-05-20

Selective Antisense Compounds and Uses Thereof

#767
20210147535
2021-05-20

Oligonucleotides for reduction of PD-L1 expression

#768
20210139909
2021-05-13

SDF-1 Binding Nucleic Acids

#769
20210139906
2021-05-13

COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION

#770
20210130823
2021-05-06

COMPOSITIONS AND METHODS

#771
20210128748
2021-05-06

Three-dimensional self-assembled nucleic acid nanoparticles and use thereof

#772
20210123054
2021-04-29

Oligonucleotides for modulating Tau expression

#773
20210123049
2021-04-29

POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF

#774
20210123048
2021-04-29

Nucleic acids for inhibiting expression of LPA in a cell

#775
20210121561
2021-04-29

Methods of producing cells resistant to HIV infection

#776
20210108212
2021-04-15

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

#777
20210108205
2021-04-15

MicroRNA Compounds and Methods for Modulating MIR-122

#778
20210102201
2021-04-08

Method of nonspecific target capture of nucleic acids

#779
20210102200
2021-04-08

SMALL MOLECULE TARGETED RECRUITMENT OF A NUCLEASE TO RNA

#780
20210095290
2021-04-01

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#781
20210095277
2021-04-01

ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1

#782
20210087570
2021-03-25

Further novel oligonucleotide-ligand conjugates

#783
20210087566
2021-03-25

Compositions and methods for modulating apolipoprotein (a) expression

#784
20210087558
2021-03-25

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#785
20210079397
2021-03-18

Nucleic acid linked to a trivalent glycoconjugate

#786
20210069337
2021-03-11

INTEGRIN TARGETING LIGANDS AND USES THEREOF

#787
20210062199
2021-03-04

Methods and compositions for inhibiting expression of LDHA

#788
20210054383
2021-02-25

Oligonucleotides for modulating TMEM106B expression

#789
20210054381
2021-02-25

Oligomers and oligomer conjugates

#790
20210054371
2021-02-25

Conjugates of Guide RNA-Cas Protein Complex

#791
20210054017
2021-02-25

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

#792
20210052631
2021-02-25

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

#793
20210046187
2021-02-18

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

#794
20210040483
2021-02-11

Modified oligonucleotides and methods of use

#795
20210040482
2021-02-11

Antisense molecules and methods for treating pathologies

#796
20210032631
2021-02-04

Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping

#797
20210032626
2021-02-04

Material for capturing circulating cells in the blood, method of preparation and use

#798
20210030656
2021-02-04

Topical silk compositions and methods of using

#799
20210024923
2021-01-28

COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION

#800
20210023235
2021-01-28

Block copolymers

#801
20210023227
2021-01-28

Methods And Compositions For Templated Assembly Of Nucleic Acid Specific Heterocompounds

#802
20210017519
2021-01-21

Modified double-stranded RNA agents

#803
20210010001
2021-01-14

Oligonucleotide analogues targeting human LMNA

#804
20210002642
2021-01-07

Methods for modulating FMR1 expression

#805
20210002640
2021-01-07

LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SURVIVAL OF MOTOR NEURON (SMA) INHIBITORS

#806
20210002638
2021-01-07

Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

#807
20210000964
2021-01-07

Fatty acids and their use in conjugation to biomolecules

#808
20200407720
2020-12-31

A DBAIT MOLECULE AGAINST ACQUIRED RESISTANCE IN THE TREATMENT OF CANCER

#809
20200399641
2020-12-24

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION

#810
20200399639
2020-12-24

Detection of microbial endotoxins in oral samples using aptamers

#811
20200392511
2020-12-17

TMPRSS6 iRNA compositions and methods of use thereof

#812
20200392510
2020-12-17

MODULATORS OF DNM2 EXPRESSION

#813
20200392509
2020-12-17

Conjugated antisense compounds and their use

#814
20200392499
2020-12-17

Short interfering nucleic acid (siNA) compositions

#815
20200392495
2020-12-17

Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages

#816
20200392494
2020-12-17

Compounds and methods for reducing SNCA expression

#817
20200392486
2020-12-17

RNA-editing oligonucleotides and uses thereof

#818
20200385727
2020-12-10

Antisense oligonucleotides targeting ATXN3

#819
20200385726
2020-12-10

Oversubscription scheduling

#820
20200385719
2020-12-10

KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#821
20200385714
2020-12-10

OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION

#822
20200385414
2020-12-10

Nucleic acid-polypeptide compositions and uses thereof

#823
20200384011
2020-12-10

POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF

#824
20200377889
2020-12-03

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

#825
20200377883
2020-12-03

Antisense oligonucleotides for modulating the function of a T cell

#826
20200376020
2020-12-03

C/EBP alpha saRNA compositions and methods of use

#827
20200369710
2020-11-26

RNA nanostructures, methods of making, and uses thereof

#828
20200362347
2020-11-19

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

#829
20200362340
2020-11-19

Modulating apolipoprotein (a) expression

#830
20200360522
2020-11-19

Nucleic acid, composition and conjugate containing same, preparation method, and use thereof

#831
20200354720
2020-11-12

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

#832
20200353276
2020-11-12

Magnetic particle conjugates and methods of activating cell signaling

#833
20200348286
2020-11-05

Oligonucleotides for inducing paternal UBE3A expression

#834
20200339998
2020-10-29

COMPLEMENT COMPONENT iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#835
20200339996
2020-10-29

ANTI-TNF COMPOUNDS

#836
20200339993
2020-10-29

Aptamer conjugates with N-heterocyclic carbene metal complexes for targeted drug delivery

#837
20200339990
2020-10-29

RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF

#838
20200339985
2020-10-29

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

#839
20200339984
2020-10-29

Multivalent oligonucleotide assemblies

#840
20200318113
2020-10-08

POLYNUCLEOTIDE CONJUGATES AND USES THEREOF

#841
20200318111
2020-10-08

RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES

#842
20200318109
2020-10-08

LNA-G process

#843
20200316201
2020-10-08

Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

#844
20200308588
2020-10-01

HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

#845
20200308585
2020-10-01

TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXIS

#846
20200299698
2020-09-24

Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

#847
20200299696
2020-09-24

Aptamer compositions and the use thereof

#848
20200299691
2020-09-24

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

#849
20200299690
2020-09-24

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

#850
20200283801
2020-09-10

Exosomal loading using hydrophobically modified oligonucleotides

#851
20200283777
2020-09-10

RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1

#852
20200283775
2020-09-10

Methods and compositions for inhibiting expression of LDHA

#853
20200283768
2020-09-10

ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS

#854
20200277610
2020-09-03

Compositions and methods for inhibiting expression of RRM2 genes

#855
20200276221
2020-09-03

ANTISENSE COMPOUNDS

#856
20200270615
2020-08-27

siRNA compositions that specifically down regulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease

#857
20200270611
2020-08-27

GALNAC DERIVATIVES

#858
20200270609
2020-08-27

Single-Stranded RNAI Oligonucleotides Targeting APOC-III

#859
20200270605
2020-08-27

Dynamic pharmacokinetic-modifying anchors

#860
20200268895
2020-08-27

Immunostimulating-Toxic RNA In Alkaline Earth Metal Formulation

#861
20200263183
2020-08-20

Complement component iRNA compositions and methods of use thereof

#862
20200263179
2020-08-20

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA

#863
20200255835
2020-08-13

COMPOSITIONS AND METHODS FOR REGULATION OF GENE EXPRESSION WITH, AND DETECTION OF, FOLINIC ACID AND FOLATES

#864
20200248188
2020-08-06

POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF

#865
20200248186
2020-08-06

Antisense oligomers targeting PCSK9

#866
20200247884
2020-08-06

Oligonucleotides for reduction of PD-L1 expression

#867
20200239883
2020-07-30

Compositions for modulating expression of C9ORF72 antisense transcript

#868
20200237663
2020-07-30

Method and composition for targeted delivery of therapeutic agents

#869
20200224201
2020-07-16

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

#870
20200224198
2020-07-16

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

#871
20200216844
2020-07-09

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

#872
20200208158
2020-07-02

Products and compositions

#873
20200208157
2020-07-02

RNA LIGAND-DISPLAYING EXOSOMES FOR SPECIFIC DELIVERY OF THERAPEUTICS TO CELL BY RNA NANOTECHNOLOGY

#874
20200208152
2020-07-02

STABILIZED SARNA COMPOSITIONS AND METHODS OF USE

#875
20200208150
2020-07-02

METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

#876
20200208149
2020-07-02

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

#877
20200197527
2020-06-25

Nucleic acid-loaded unit polyion complex

#878
20200197526
2020-06-25

REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF

#879
20200190523
2020-06-18

PKLR inhibition in the treatment of NAFLD and HCC

#880
20200190522
2020-06-18

COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION

#881
20200190519
2020-06-18

Brush polymer-assisted compaction of oligonucleotides

#882
20200190517
2020-06-18

Organic compositions to treat EPAS1-related diseases

#883
20200181614
2020-06-11

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

#884
20200165618
2020-05-28

Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

#885
20200165616
2020-05-28

Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

#886
20200165612
2020-05-28

Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor

#887
20200157550
2020-05-21

RNAi inhibition of alpha-ENaC expression

#888
20200157548
2020-05-21

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#889
20200157546
2020-05-21

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION

#890
20200147123
2020-05-14

Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection

#891
20200140858
2020-05-07

Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases

#892
20200138846
2020-05-07

Enzymatic replacement therapy and antisense therapy for Pompe disease

#893
20200123551
2020-04-23

Compositions and methods for modulating growth hormone receptor expression

#894
20200123543
2020-04-23

Modified oligonucleotides targeting SNPs

#895
20200115709
2020-04-16

Functionally-modified oligonucleotides and subunits thereof

#896
20200102560
2020-04-02

POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF

#897
20200095583
2020-03-26

Methods and compositions for managing vascular conditions

#898
20200095580
2020-03-26

Products and compositions

#899
20200085758
2020-03-19

CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES

#900
20200080087
2020-03-12

Twist signaling inhibitor compositions and methods of using the same